Table 3 Genetic features and clinical outcome of ABL-class or JAK-STAT pathway fusion (AJS)-positive patients
Case no. | Age group | In-frame gene fusion | WBC | DEX / PREDNI | MRD D15 | MRD D29 | MRD D79 | Risk Group | alloSCT (Y/N) | Event (Y/N) | Comment |
|---|---|---|---|---|---|---|---|---|---|---|---|
Case 1 | Adult | ETV6-ABL1 | 270 | DEX | ─ | ─ | ─ | ─ | N | Y | Induction death |
Case 2 | Adult | ZC3HAV1-ABL2 | 72 | PREDNI | 30.5% | 6.5% | 0.01% | IR | Y | Y | Death of sepsis after alloSCT in CR1 |
Case 3 | Adult | EBF1-PDGFRB | 258 | DEX | 45.3% | 0.93% (POST A1) | 0.7% (POST B1) | HR-SCT | Y | Y | Relapse after alloSCT and death |
Case 4 | Adult | IGH-CRLF2 | 4 | PREDNI | 11.6% | 20.3% | 3.4% | HR-SCT | Y | Y | Relapse after alloSCT and alive in CR2 |
Case 5 | Adult | IGH-CRLF2 | 104 | DEX | 44.3% | 8% | 1.65% | HR-SCT | Y | N | Alive after alloSCT in CR1 |
Case 6 | Pediatric | IGH-CRLF2 | 35 | PREDNI | 0.22% | < 0.1% | 0.3% | HR-SCT | Y | N | Alive after alloSCT in CR1 |
Case 7 | Pediatric | BCR-JAK2 | 5 | PREDNI | 1.8% | 0.33% | < 0.1% | IR | N | N | Alive in CR1 |